Zogenix Inc (ZGNX):製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】Zogenix Inc (ZGNX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C9826)・商品コード:DATA904C9826
・発行会社(調査会社):GlobalData
・発行日:2018年11月
・ページ数:64
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Zogenix Inc (Zogenix) is a pharmaceutical company with focus on central nervous system (CNS) disorders. It develops and commercializes therapies for rare CNS disorders. The company’s lead product candidate ZX008 (low dose fenfluramine) is intended for the treatment of Dravet syndrome and Lennox-Gastaut syndrome (LGS). ZX008 is in Phase 3 clinical trials and has orphan drug designation in the US and EU and secured Fast Track designation and breakthrough therapy designation from the US FDA. The company operates in the UK through its subsidiary Zogenix International, Ltd. Zogenix is headquartered in Emeryville, California, the US.

Zogenix Inc (ZGNX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Zogenix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Zogenix Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Zogenix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Zogenix Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Zogenix Inc, Medical Devices Deals, 2012 to YTD 2018 10
Zogenix Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Zogenix Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Zogenix Enters Into Co-Promotion Agreement With Mallinckrodt For Sumavel DosePro 12
Zogenix Amends Co-Marketing Agreement With Battelle Memorial Institute For DosePro 13
Licensing Agreements 14
Zogenix Enters Into Licensing Agreement With Altus Formulation For Zohydro ER 14
Zogenix International Amends Licensing Agreement with University of Antwerp and University of Leuven 15
Equity Offering 16
Zogenix Prices Public Offering of Shares for USD312 Million 16
Zogenix Raises USD289 Million in Public Offering of Shares 18
Zogenix Raises USD98.3 Million in Public Offering of Shares 20
Zogenix Raised USD10.8 Million in Public Offering Of Shares 22
Zogenix Completes Public Offering Of Shares For US$69 Million 23
Zogenix Completes Public Offering Of Units For US$70 Million 25
Asset Transactions 26
Pernix Acquires Zohydro ER Business from Zogenix 26
Endo International Completes Acquisition of Sumavel DosePro Migraine Therapy Business from Zogenix 28
Acquisition 29
Zogenix Acquires Brabant Pharma for USD130 Million 29
Zogenix Inc – Key Competitors 30
Zogenix Inc – Key Employees 31
Zogenix Inc – Locations And Subsidiaries 32
Head Office 32
Other Locations & Subsidiaries 32
Recent Developments 33
Financial Announcements 33
Aug 06, 2018: Zogenix provides corporate update and reports second quarter financial results 33
May 09, 2018: Zogenix Provides Corporate Update and Reports First Quarter Financial Results 35
Mar 06, 2018: Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2017 Financial Results 37
Nov 07, 2017: Zogenix Provides Corporate Update and Reports Third Quarter 2017 Financial Results 39
Aug 08, 2017: Zogenix Provides Corporate Update and Reports Second Quarter 2017 Financial Results 41
May 04, 2017: Zogenix Reports First Quarter 2017 Financial Results 43
Mar 09, 2017: Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2016 Financial Results 44
Corporate Communications 46
Jul 02, 2018: Zogenix Appoints Ashish Sagrolikar As New Global Chief Commercial Officer 46
Jan 05, 2017: Zogenix Announces CFO Transition 47
Product News 48
05/22/2017: Zogenix Announces Presentation of ZX008 Mechanism of Action Data at Annual Meeting of Society of Biological Psychiatry 48
02/06/2018: Zogenix Announces Receipt of FDA Breakthrough Therapy Designation for ZX008 in Dravet Syndrome 49
Product Approvals 50
Jun 22, 2017: Zogenix Receives Orphan Drug Designation from FDA for ZX008 in Treatment of Lennox Gastaut Syndrome 50
Mar 01, 2017: Zogenix Receives Orphan Drug Designation in the European Union for ZX008 in Lennox Gastaut Syndrome 51
Clinical Trials 52
Jan 31, 2018: Zogenix Completes Enrollment in Second ZX008 Phase 3 Clinical Trial in Dravet Syndrome 52
Dec 04, 2017: Zogenix Announces New Positive Efficacy and Safety Data from Pivotal Phase III Clinical Trial of ZX008 in Dravet Syndrome 53
Nov 29, 2017: Zogenix Announces Initiation of Phase 3 Trial for ZX008 in Lennox-Gastaut Syndrome 55
Nov 28, 2017: Zogenix To Host Call with Pediatric Epilepsy Expert Joseph Sullivan, M.D., on Dravet Syndrome and ZX008 on Monday, December 4 56
Nov 21, 2017: New Data from Zogenix’s Phase 3 Trial of ZX008 in Dravet Syndrome (Study 1) and Findings on Disease Impact to be Presented at 71st American Epilepsy Society Annual Meeting 57
Oct 16, 2017: Zogenix Provides Update on ZX008 59
Sep 29, 2017: Zogenix Announces Positive Top-line Results from Pivotal Phase 3 Clinical Trial of ZX008 in Dravet Syndrome 60
May 04, 2017: Zogenix Provides Update On Phase 3 Study Of ZX008 61
Apr 27, 2017: Zogenix Completes Enrollment in First ZX008 Phase 3 Clinical Trial in Dravet Syndrome 62
Feb 13, 2017: Zogenix Announces Initiation of Clinical Efficacy Portion of Study 1504 for ZX008 in Dravet Syndrome 63
Appendix 64
Methodology 64
About GlobalData 64
Contact Us 64
Disclaimer 64

List of Tables
Zogenix Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Zogenix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Zogenix Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Zogenix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Zogenix Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Zogenix Inc, Medical Devices Deals, 2012 to YTD 2018 10
Zogenix Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Zogenix Enters Into Co-Promotion Agreement With Mallinckrodt For Sumavel DosePro 12
Zogenix Amends Co-Marketing Agreement With Battelle Memorial Institute For DosePro 13
Zogenix Enters Into Licensing Agreement With Altus Formulation For Zohydro ER 14
Zogenix International Amends Licensing Agreement with University of Antwerp and University of Leuven 15
Zogenix Prices Public Offering of Shares for USD312 Million 16
Zogenix Raises USD289 Million in Public Offering of Shares 18
Zogenix Raises USD98.3 Million in Public Offering of Shares 20
Zogenix Raised USD10.8 Million in Public Offering Of Shares 22
Zogenix Completes Public Offering Of Shares For US$69 Million 23
Zogenix Completes Public Offering Of Units For US$70 Million 25
Pernix Acquires Zohydro ER Business from Zogenix 26
Endo International Completes Acquisition of Sumavel DosePro Migraine Therapy Business from Zogenix 28
Zogenix Acquires Brabant Pharma for USD130 Million 29
Zogenix Inc, Key Competitors 30
Zogenix Inc, Key Employees 31
Zogenix Inc, Other Locations 32
Zogenix Inc, Subsidiaries 32

List of Figures
Zogenix Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Zogenix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Zogenix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Zogenix Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Zogenix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Zogenix Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Zogenix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Zogenix Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Zogenix Inc, Medical Devices Deals, 2012 to YTD 2018 10

★調査レポート[Zogenix Inc (ZGNX):製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C9826)販売に関する免責事項を必ずご確認ください。
★調査レポート[Zogenix Inc (ZGNX):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆